Abbott’s Post

As a bonus mother with an adult child with T1D and being pre-diabetic myself due to genetics/family history/3 pregnancies with gestational diabetes, I cannot emphasize enough how life changing CGM’s (continuous glucose monitoring) and has turned a 180 on diabetes management. My bonus daughter now has a normal A1C thanks to her CGM & insulin pump, and I have invested in utilizing the #Stelo CGM which is brand new for those of us who are prediabetic & trying to prevent transformation to T2D. Lifechanging is an understatement. I now know what foods trigger high glucose and can see how certain foods, stressors/anxiety, sleep (yes I can shoot up to 200 at 4:30 in the morning when cortisol naturally kicks in) & physical activity affect my BGL’s so I can act on these life happenings to prevent diabetes. The problem? Insurances refuse to pay for CGM’s for prediabetics — which is an atrocity. I pay out of pocket and gladly do so because my health is worth it. Are you prediabetic? I recommend #Stelo wholeheartedly. Stelo is made by Dexcom. I am so incredibly grateful to Dexcom for this incredible healthcare tool to help keep me from transitioning to a serious disease. I am eagerly awaiting Abbott to come out with the same technology for prediabetics as I will be able to obtain these much easier and less costly due to my employer’s support! Check out Abbott’s story! #stelo #insurancereform https://lnkd.in/gektEYbP

WEBINAR 03/28 from 2-3pm ET: What works, for whom, and what’s worth the money when it comes to digital health? Founded by the Peterson Center on Healthcare in 2023, The Peterson Health Technology Institute (PHTI) provides independent evaluations of innovative healthcare technologies. Don't miss PHTI's webinar exploring its assessment findings on digital diabetes management tools that people with Type 2 diabetes use to track and manage their condition. Register below:

🌍💙 Embracing technology to build a healthier future! Managing diabetes can be overwhelming, but innovative tech solutions are transforming lives and building societal resilience. From real-time data analysis to personalised support, technology empowers individuals to take control of their health and bridges the gap between patients and healthcare providers. At DDM, we are proud to be at the forefront of these advancements, making a difference in diabetes care and prevention. Read more about the impact of tech in diabetes management from Swiss Re

9 million patients with type 2 diabetes. 1,100 diabetologist practices -> 8,182 patients per specialist. 60,000 general practitioners ->150 patients per GP. Quite obvious that it will be close to impossible to deliver high-quality care to everyone. Especially, since the number of patients is expected to reach 12M by 2024 and then meeting a substantially smaller workforce. We need to fix this. In this video, Perfood founder and Chief Medical Officer Torsten Schröder, MD, PhD explains how we can change the tractory. 1. Truly innovative care solutions, harvesting the power of artificial intelligence. 2. Involving patients: empowering and enabling them to manage their health. Luckily, with hashtag #glucura Perfood developed an innovative solution applying the power of hashtag #cgm and hashtag #artificialintelligence. At the Deutsche Diabetes Gesellschaft (DDG) congress 2024, Dr. Jesuthas Ajendra walked providers through our pilot data in a poster session. Not too spoil anything, but keep an eye open for our soon to be published long-term follow-up data ;)

"𝐒𝐦𝐚𝐫𝐭 𝐈𝐧𝐬𝐮𝐥𝐢𝐧 𝐏𝐞𝐧𝐬: 𝐃𝐫𝐢𝐯𝐢𝐧𝐠 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧 𝐚𝐧𝐝 𝐆𝐫𝐨𝐰𝐭𝐡 𝐢𝐧 𝐭𝐡𝐞 𝐆𝐥𝐨𝐛𝐚𝐥 𝐃𝐢𝐚𝐛𝐞𝐭𝐞𝐬 𝐌𝐚𝐫𝐤𝐞𝐭" | 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐏𝐃𝐅 : https://lnkd.in/dn-qDpjm 🚀 Revolutionizing Diabetes Management 🩺 Global Insight Services As the demand for convenient and precise insulin delivery grows, Insulin Pens are transforming the way millions of people manage diabetes. With innovations in smart technology and eco-friendly designs, insulin pens are helping to improve patient outcomes and accessibility. Whether you're a healthcare professional, patient, or innovator, it's inspiring to see how far diabetes care has come—and where it's heading next! 💡 Buy Now @ https://lnkd.in/dENaeWpe #DiabetesCare #InsulinPens #SmartHealthcare #MedicalInnovation #DiabetesTechnology #HealthcareSolutions #PatientCare #DigitalHealth #PharmaTech #SustainableHealthcare #ChronicCare #HealthcareInnovation

Senior Director of Global Medical Affairs, Jennifer McVean, MD sat down with Stacey Simms on the Diabetes Connections podcast. Dr. McVean talks her own journey with #type1diabetes, the benefits of the #MiniMed780G system, why CGM alone is not enough, and more!    “Hyperglycemia is a public health crisis for type 1 [Diabetes] and I think we can fix it. It’s all about automated insulin delivery,” said Dr. McVean. “CGM is critically helpful and impactful, but at the end of the day, it doesn’t take action. That’s where I feel we need to shift back to a system that incorporates the CGM and is able to take action for the person living with diabetes. When you look at AID system use and outcomes, that’s where we really see the ability to help people achieve that Time in Range over 70%.”      Listen to the full Diabetes Connections podcast episode with Dr. McVean: https://bit.ly/DC1_638     #pwd #diabetescare  The MiniMedTM 780G system is for type 1 ages 7 and over. Prescription required. WARNING: Do not use SmartGuard™ feature for people who require less than 8 units or more than 250 units of insulin/day. See bit.ly/780gRisks   

#Medtech and #healthinnovation are changing the lives of people with diabetes! John Whyte, MD, chief medical officer of WebMD, offers key insights during this American Diabetes Association webinar on how technologies are sustaining and saving lives. #Diabetes lifestyle and health improve with blood glucose monitoring and higher insulin control. Dr. Whyte is the bestselling author of "Take Control of Your Diabetes" on Amazon. Watch here: https://lnkd.in/gGURi5Mu

How is Noom Health breaking the GLP-1 cost cycle? Join Jennifer A Jones (Noom Health’s Clinical Solutions Director), Chantell Reagan (Senior Director, National Pharmacy Clinical Leader) for WTW, and Cody Fair as they break down the nation’s obesity crisis and discuss how employers can broaden access to GLP-1s, regardless of an organization’s current coverage policies for obesity medications. In this on-demand webinar, you’ll learn about Noom Health’s two new tailored solutions that can enhance health outcomes and cost savings, including for those on GLP-1s or other anti-obesity medications. #glp1 #aom https://lnkd.in/g98bPsU3

If you are an Employer who: 1) Covers GLP-1's and needs a partner to apply clinical/cost guardrails to reign in unnecessary spend. 2) Is contemplating covering GLP-1's and needs a trusted partner to navigate this dynamic category. 3) Needs to address medical costs by preventing downstream spend (ie. MSK, Type 2- Diabetes) through cardiometabolic health. 4). Understands that Obesity is a chronic condition and needs to be treated as such; through personalized, clinical patient care plans. . 5) Believe that medication without skill-building and lifestyle support is not a sustainable solution to longitudinal health.... ....You should consider us here at Wondr Health.

In recent news, the Diabetes Sector Group of MedTech Europe has achieved a significant milestone that is set to revolutionise diabetes management across Europe. The Sector Group recently finalised its access paper, highlighting the benefits of digitally enabled care. It also dives into the barriers individuals with diabetes face when accessing digitally-enabled care. The access paper has opened critical discussions regarding access to digitally enabled care, and will soon pave the way for addressing such issues at the European and national levels. Learn more: https://heyor.ca/sC5MgM #Diabetes #DigitallyEnabledCare #Type2 #MedTech #DiabetesSectorGroup